Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00540644 · ClinicalTrials.gov registry record · Phase 2

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Attaya Suvannasankha.

Completed
Registry status
Phase 2
Development phase
70
Enrollment target
1
Study location

NCT00540644: Completed Phase 2 study of Multiple Myeloma, sponsored by Attaya Suvannasankha.

NCT00540644 is a Phase 2 study of Multiple Myeloma that has completed, run by Attaya Suvannasankha. The registered enrollment target is 70 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00540644, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Attaya Suvannasankha.

COMPLETED
Registry status
Phase 2
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Prednisone
  • DRUG lenalidomide (Revlimid®)

Study Locations (1)

Indiana

  • Indiana University Cancer Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2007-10
Est. Completion 2014-08
Phase Phase 2

Sponsor

Attaya Suvannasankha

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00540644

The ClinicalTrials.gov registry entry for NCT00540644 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The listed sponsor is Attaya Suvannasankha, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT00540644 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT00540644 about?

NCT00540644 is a clinical study titled "Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma". The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.

What is the current status of trial NCT00540644?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2007-10. Estimated completion is 2014-08.

What conditions does trial NCT00540644 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00540644?

The interventions under investigation include: Cyclophosphamide (DRUG), Prednisone (DRUG), lenalidomide (Revlimid®) (DRUG).

Who is sponsoring clinical trial NCT00540644?

This trial is sponsored by Attaya Suvannasankha, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00540644 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.